Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis

Area of Science:

• Pharmacology
• Oncology
• Angiogenesis Research

Background:

• Small molecule inhibitors are crucial in targeted cancer therapy.
• Kinase inhibitors play a significant role in blocking signaling pathways involved in tumor growth and angiogenesis.
• Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) are key regulators of angiogenesis.

Purpose of the Study:

• To evaluate the pharmacokinetic properties of RO4396686 in rodents.
• To assess the anti-angiogenic potential of RO4396686 in a mouse corneal neovascularization assay.
• To determine the efficacy of RO4396686 in inhibiting tumor growth in a xenograft model.

Main Methods:

• RO4396686 was characterized for its pharmacokinetic profile in rodent models.
• Angiogenesis was induced by VEGF in a mouse corneal neovascularization assay to test RO4396686's inhibitory effects.
• Tumor growth inhibition was evaluated using an H460a xenograft model treated with RO4396686.

Main Results:

• RO4396686 exhibited favorable pharmacokinetic properties in rodents.
• The compound demonstrated significant inhibition of VEGF-induced angiogenesis in the corneal assay.
• RO4396686 achieved substantial tumor growth inhibition in the H460a xenograft model at doses of 50mg/kg.

Conclusions:

• RO4396686 is a potent small molecule inhibitor of KDR, FGFR, and PDGFR with promising anti-angiogenic and anti-tumor activities.
• The compound's favorable pharmacokinetics and demonstrated efficacy in preclinical models suggest its potential as a therapeutic agent for cancer treatment.